Herpes simplex virus type 1 and Alzheimer’s disease: increasing evidence for a major role of the virus
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Herpes simplex virus type 1 (HSV1), when present in brain of carriers of the type 4 allele of the apolipoprotein E gene (APOE), has been implicated as a major factor in Alzheimer's disease (AD). It is proposed that virus is normally latent in many elderly brains but reactivates periodically (as in the peripheral nervous system) under certain conditions, for example stress, immunosuppression, and peripheral infection, causing cumulative damage and eventually development of AD. Diverse approaches have provided data that explicitly support, directly or indirectly, these concepts. Several have confirmed HSV1 DNA presence in human brains, and the HSV1-APOE-ε4 association in AD. Further, studies on HSV1-infected APOE-transgenic mice have shown that APOE-e4 animals display a greater potential for viral damage. Reactivated HSV1 can cause direct and inflammatory damage, probably involving increased formation of beta amyloid (Aβ) and of AD-like tau (P-tau)-changes found to occur in HSV1-infected cell cultures. Implicating HSV1 further in AD is the discovery that HSV1 DNA is specifically localized in amyloid plaques in AD. Other relevant, harmful effects of infection include the following: dynamic interactions between HSV1 and amyloid precursor protein (APP), which would affect both viral and APP transport; induction of toll-like receptors (TLRs) in HSV1-infected astrocyte cultures, which has been linked to the likely effects of reactivation of the virus in brain. Several epidemiological studies have shown, using serological data, an association between systemic infections and cognitive decline, with HSV1 particularly implicated. Genetic studies too have linked various pathways in AD with those occurring on HSV1 infection. In relation to the potential usage of antivirals to treat AD patients, acyclovir (ACV) is effective in reducing HSV1-induced AD-like changes in cell cultures, and valacyclovir, the bioactive form of ACV, might be most effective if combined with an antiviral that acts by a different mechanism, such as intravenous immunoglobulin (IVIG).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
Wozniak, M., Mee, A., & Itzhaki, R. (2009) · The Journal of Pathology · doi:10.1002/path.2449 · Cited by 464
Self-citationLetenneur, L., Pérès, K., Fleury, H., Garrigue, I., Barberger-Gateau, P., Helmer, C., Orgogozo, J.-M., Gauthier, S., & Dartigues, J.-F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003637 · Cited by 252
Inflammation Induced by Infection Potentiates Tau Pathological Features in Transgenic Mice
Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, T. E., & LaFerla, F. M. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.012 · Cited by 210 · cited 2×
“Sy et al. (2011) postulated that infections might promote the development of AD by exacerbating pre-existing neuroinflammation, hence accelerating cognitive decline.”
BackgroundLurain, N. S., Hanson, B. A., Martinson, J., Leurgans, S. E., Landay, A. L., Bennett, D. A., & Schneider, J. A. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit210 · Cited by 159
Anthony, I. C., Ramage, S. N., Carnie, F. W., Simmonds, P., & Bell, J. E. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0037-0 · Cited by 158
Infectious burden and cognitive function: The Northern Manhattan Study
Katan, M., Moon, Y. P., Paik, M. C., Sacco, R. L., Wright, C. B., & Elkind, M. S. V. (2013) · Neurology · doi:10.1212/wnl.0b013e3182896e79 · Cited by 141
Tarter, K. D., Simanek, A. M., Dowd, J. B., & Aiello, A. E. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit616 · Cited by 78
A sero-epidemiological study of conventional infectious agents in Alzheimer’s disease
RENVOIZE, E. B., AWAD, L. O., & HAMBLING, M. H. (1987) · Age and Ageing · doi:10.1093/ageing/16.5.311 · Cited by 59
Cited by
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
“Related pathogens include Helicobacter pylori, various bacteria of the liver, gut, lungs (pneumonia) and mouth, as well as viruses to include Epstein Barr virus, CMV, HIV, oral herpes HSV-1, genital herpes HSV-2, human herpesvirus (HHV)-6A/HHV-7 (recently reviewed in [530]).”
BackgroundInfluentialHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Readhead, B., Haure-Mirande, J.-V., Funk, C. C., Richards, M. A., Shannon, P., Haroutunian, V., Sano, M., Liang, W. S., Beckmann, N. D., Price, N. D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.023 · Cited by 708
“Beginning with Crapper McLachlan in 1980 (Middleton et al., 1980), several investigators have proposed that AD is an SSPE-like illness, caused by a slow virus form of herpes simplex (Itzhaki, 2014).”
BackgroundEimer, W. A., Vijaya Kumar, D. K., Navalpur Shanmugam, N. K., Rodriguez, A. S., Mitchell, T., Washicosky, K. J., György, B., Breakefield, X. O., Tanzi, R. E., & Moir, R. D. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.030 · Cited by 674
The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540
“…a potential danger and possibly not only hyperphosphorylate tau but also induce a conformational change in the protein (Ball, 1982; Jamieson et al., 1991; Wozniak et al., 2009a; Itzhaki and Wozniak, 2010; Wozniak and Itzhaki, 2010; Deruelle and Favoreel, 2011; Ball et al., 2013; Itzhaki, 2014)?”
BackgroundMicrobes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
Self-citationThe Infectious Etiology of Alzheimer’s Disease
Sochocka, M., Zwolińska, K., & Leszek, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170313122937 · Cited by 399
Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0611-x · Cited by 356
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
“For example, Aß deposits have been noted in wild-type mice infected with Chlamydia pneumoniae (Little et al., 2004, 2014; Boelen et al., 2007), HSV1 (Wozniak et al., 2007), pseudorabies virus (Tanaka and Nagashima, 2017), or Toxoplasma gondii (Torres et al., 2018), while transgenic-AD mice infected with Porphyromonas…”
BackgroundInfluentialCNS Infection and Immune Privilege
Forrester, J. V., McMenamin, P. G., & Dando, S. J. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0070-8 · Cited by 313
Lopez‐Rodriguez, A. B., Hennessy, E., Murray, C. L., Nazmi, A., Delaney, H. J., Healy, D., Fagan, S. G., Rooney, M., Stewart, E., Lewis, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12341 · Cited by 293
Human gut microbiota: the links with dementia development
Alkasir, R., Li, J., Li, X., Jin, M., & Zhu, B. (2017) · Protein & Cell · doi:10.1007/s13238-016-0338-6 · Cited by 285
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
“This contrasts with clinically apparent acute HSV encephalitis, where detection of HSV-1 DNA in cerebrospinal fluid (CSF) is commonly used for diagnosis [32].”
BackgroundInfluentialWang, Q., Davis, P. B., Gurney, M. E., & Xu, R. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12296 · Cited by 257
Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease
Itzhaki, R. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00324 · Cited by 256
Self-citationDifferent Brain Regions are Infected with Fungi in Alzheimer’s Disease
Pisa, D., Alonso, R., Rábano, A., Rodal, I., & Carrasco, L. (2015) · Scientific Reports · doi:10.1038/srep15015 · Cited by 248
Tohidpour, A., Morgun, A. V., Boitsova, E. B., Malinovskaya, N. A., Martynova, G. P., Khilazheva, E. D., Kopylevich, N. V., Gertsog, G. E., & Salmina, A. B. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00276 · Cited by 178
“Various factors lead to activation of HSV-1 from the latency phase, such as stress and ultraviolet radiation (Itzhaki, 2014).”
BackgroundThe Possibility of an Infectious Etiology of Alzheimer Disease
Ashraf, G. M., Tarasov, V. V., Makhmutovа, A., Chubarev, V. N., Avila-Rodriguez, M., Bachurin, S. O., & Aliev, G. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1388-y · Cited by 175
Spitzer, P., Condic, M., Herrmann, M., Oberstein, T. J., Scharin-Mehlmann, M., Gilbert, D. F., Friedrich, O., Grömer, T., Kornhuber, J., Lang, R., et al. (2016) · Scientific Reports · doi:10.1038/srep32228 · Cited by 128
Infectious agents and Alzheimer's disease
Piekut, T., Hurła, M., Banaszek, N., Szejn, P., Dorszewska, J., Kozubski, W., & Prendecki, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102073 · Cited by 123
Polymicrobial Infections In Brain Tissue From Alzheimer’s Disease Patients
Pisa, D., Alonso, R., Fernández-Fernández, A. M., Rábano, A., & Carrasco, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05903-y · Cited by 114
Nimgaonkar, V. L., Yolken, R. H., Wang, T., Chang, C.-C. H., McClain, L., McDade, E., Snitz, B. E., & Ganguli, M. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000133 · Cited by 109
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
“It was reported that many specific viral, bacterial, and fungal pathogens are suspected to play a role in the progression of neurodegeneration due to AD, including herpes simplex virus type 1 (HSV-1), Chlamydia pneumonia, spirochetes, and Candida [70,71].”
BackgroundNeurocognitive impacts of arbovirus infections
Clé, M., Eldin, P., Briant, L., Lannuzel, A., Simonin, Y., Van de Perre, P., Cabié, A., & Salinas, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01904-3 · Cited by 67
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Herpes simplex virus and Alzheimer’s disease: a Mendelian randomization study
Kwok, M. K., & Schooling, C. M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.025 · Cited by 55
When the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Potential Role for Herpesviruses in Alzheimer’s Disease
Duggan, M. R., Torkzaban, B., Ahooyi, T. M., & Khalili, K. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200814 · Cited by 13
“…the vast prevalence of HHVs across populations, as well as the asymptomatic nature of latent neurotropic infections, future investigations should screen for infected yet non-demented individuals who might otherwise be categorized as controls and potentially confound neurocognitive assessments [39].”
Goudsmit, J. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0144-8 · Cited by 13
“Does AD start with p-tau seeding, aggregation and spreading within the brain at young age [27], or with amyloid b seeding, aggregation and spreading in midlife [35], or with the accelerated combination of the two at older age? Or are tau, amyloid and aging all confounders and is there a yet still unknown cause of AD,…”
BackgroundA reappraisal on amyloid cascade hypothesis: The role of chronic infection in Alzheimer’s disease
Phuna, Z. X., & Madhavan, P. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2045290 · Cited by 12
Metadata
- Authors
- Itzhaki, R. F.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-08-11
- Volume
- 6
- Pages
- 202-202
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2041561421
- Cited by
- 199
- References
- 8
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.